This site is intended for healthcare professionals outside the US.

  1. Home
  2. aNET
  3. pNET
  4. Efficacy

In advanced, progressive pNET

AFINITOR more than doubled median PFS vs placebo1,2

Kaplan-Meier curve for progression-free survival in the RADIANT-3 study of AFINITOR
AFINITOR arm, 95% CI: 8.4-13.9. Placebo arm, 95% CI: 3.1-5.4. HR=0.35. 95% CI: 0.27-0.45. P<0.001 by stratified one-sided log-rank test.
  • AFINITOR extended median PFS in patients with advanced, progressive pNET by more than 6 months (P<0.001)1,2
  • Treatment with AFINITOR resulted in a 65% reduction in risk of progression or death (HR=0.35; 95% CI: 0.27-0.45; P<0.001)1,2
Abbreviations:
CI, confidence interval; HR, hazard ratio; PFS, progression-free survival; pNET; pancreatic neuroendocrine tumor(s).

Final OS results from RADIANT-3

Patient population of the RADIANT-4 study by primary site of tumor originKaplan-Meier curve for overall survival in the RADIANT-3 study of AFINITOR

AFINITOR arm, 95% CI: 35.61-51.75. Placebo arm, 95% CI: 29.14-45.77. HR= 0.94. 95% CI: 0.73-1.20. Log-rank P=0.300.
  • 44.0-month median OS in patients treated with AFINITOR compared to 37.7 months for the placebo/crossover arm; not statistically significant but clinically meaningful3
    • (AFINITOR arm, 95% CI: 35.61-51.75. Placebo arm, 95% CI: 29.14-45.77. HR=0.94. 95% CI: 0.73-1.20. Log-rank P=0.300)3
    • Crossover to AFINITOR by 85% of the patients initially randomized to the placebo arm may have confounded the comparative analysis3
  • Despite an 85% crossover, AFINITOR demonstrated a clinically meaningful 6.3-month median improvement of OS3
Abbrevations:
CI, confidence interval; HR, hazard ratio; OS, overall survival; pNET; pancreatic neuroendocrine tumor(s); RADIANT, RAD001 in Advanced Neuroendocrine Tumors.
References:
  1. AFINITOR [summary of product characteristics]. Basel, Switzerland: Novartis Pharma AG; August 2017.
  2. Yao JC, Shah MH, Ito T, et al; for the RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514-523.
  3. Yao JC, Pavel M, Lombard-Bohas C, et al. Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: final overall survival results of a randomized, double-blind, placebo-controlled, multicenter phase III trial (RADIANT-3). Paper presented at: 2014 Congress of the European Society for Medical Oncology (ESMO); September 26-30, 2014; Madrid, Spain.